✦ LIBER ✦

Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial

✍ Scribed by Michael E. Weinblatt; Edward C. Keystone; Daniel E. Furst; Larry W. Moreland; Michael H. Weisman; Charles A. Birbara; Leah A. Teoh; Steven A. Fischkoff; Elliot K. Chartash

Publisher: John Wiley and Sons
Year: 2003
Tongue: English
Weight: 115 KB
Volume: 48
Category: Article
ISSN: 0004-3591
DOI: 10.1002/art.10697

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Erratum: M.E. Weinblatt, E.C. Keystone,

Erratum: M.E. Weinblatt, E.C. Keystone, D.E. Furst, L.W. Moreland, M.H. Weisman, C.A. Birbara, L.A. Teoh, S.A. Fischkoff, and E.K. Chartash. Adalimumab, a Fully Human Anti-Tumor Necrosis Factor α Monoclonal Antibody, for the Treatment of Rheumatoid Arthritis in Patients Taking Concomitant Methotrexate: The ARMADA Trial, Arthritis & Rheumatism (2003) 48(1) 35-45.

📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 39 KB 👁 1 views

## Abstract The original article to which this Erratum refers was published in Arthritis & Rheumatism(2003) 48(1) 35–45 In the article by Weinblatt et al published in the January 2003 issue of __Arthritis & Rheumatism__ (pp 35–45), there was an error in data reported in the first paragraph of the

Radiographic, clinical, and functional o

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial

✍ Edward C. Keystone; Arthur F. Kavanaugh; John T. Sharp; Hyman Tannenbaum; Ye Hua 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 167 KB 👁 2 views

Treatment with monoclonal anti–tumor nec

Treatment with monoclonal anti–tumor necrosis factor α antibody results in an accumulation of Th1 CD4+ T cells in the peripheral blood of patients with rheumatoid arthritis

✍ Madelon M. Maurice; Wiebo L. Van Der Graaff; Angela Leow; Ferdinand C. Breedveld 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 161 KB 👁 1 views

Evidence of radiographic benefit of trea

Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: A detailed subanalysis of data from the anti–tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study

✍ J. S. Smolen; C. Han; M. Bala; R. N. Maini; J. R. Kalden; D. van der Heijde; F. 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 143 KB 👁 2 views

Golimumab, a human anti–tumor necrosis f

Golimumab, a human anti–tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four–week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis

✍ Paul Emery; Roy M. Fleischmann; Larry W. Moreland; Elizabeth C. Hsia; Ingrid Str 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 135 KB

Erratum: Golimumab, a human anti-tumor n

Erratum: Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis

✍ Paul Emery; Roy M. Fleischmann; Larry W. Moreland; Elizabeth C. Hsia; Ingrid Str 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 38 KB